LOC285636 Lentiviral Activation Particles (h): sc-415435-LAC

C5orf51 encodes the poorly characterized human protein LOC285636, a predicted regulatory factor with limited functional annotation and expression- and context-dependent roles that remain to be defined. Emerging transcriptomic associations suggest LOC285636 may participate in gene regulatory networks that influence cell-state decisions, including proliferation and differentiation programs, through modulation of downstream transcriptional responses. Altered C5orf51/LOC285636 expression has been reported in select disease-relevant datasets, supporting its use as a candidate locus for mechanistic studies in stress response, lineage specification, and other cellular processes. Because pathway placement is not yet fully resolved, systematic perturbation is valuable for linking LOC285636 to signaling nodes and phenotypes in human cellular models.

LOC285636 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient C5orf51 upregulation across a broader range of human cell types.

LOC285636 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the C5orf51 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous LOC285636 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native C5orf51 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.